bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S2 from High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy
Authors: Eranki Avinash , Srinivasan Priya , Ries Mario , Kim AeRang , Lazarski Christopher A. , Rossi Christopher T. , Khokhlova Tatiana D. , Wilson Emmanuel , Knoblach Susan M. , Sharma Karun V. , Wood Bradford J. , Moonen Chrit , Sandler Anthony D. , Kim Peter C.W.
Published: April 2023

Figure S2. Immune cell infiltration within neuroblastoma tumors pre- and at 24, 48, & 72-hrs post-HIFU alone.
Figure S1 from High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy
Authors: Eranki Avinash , Srinivasan Priya , Ries Mario , Kim AeRang , Lazarski Christopher A. , Rossi Christopher T. , Khokhlova Tatiana D. , Wilson Emmanuel , Knoblach Susan M. , Sharma Karun V. , Wood Bradford J. , Moonen Chrit , Sandler Anthony D. , Kim Peter C.W.
Published: April 2023

Figure S1. Time-lapse of tumor growth in untreated mice and mice treated with HIFU+ Î±CTLA-4 + Î±PD-L1, HIFU alone, and Î±CTLA-4 + Î±PD-L1.
Table S1 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
Authors: Bernard Vincent , Semaan Alexander , Huang Jonathan , San Lucas F. Anthony , Mulu Feven C. , Stephens Bret M. , Guerrero Paola A. , Huang Yanqing , Zhao Jun , Kamyabi Nabiollah , Sen Subrata , Scheet Paul A. , Taniguchi Cullen M. , Kim Michael P. , Tzeng Ching-Wei , Katz Matthew H. , Singhi Aatur D. , Maitra Anirban , Alvarez Hector A.
Published: April 2023

Patient characteristics
Figure S4 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
Authors: Bernard Vincent , Semaan Alexander , Huang Jonathan , San Lucas F. Anthony , Mulu Feven C. , Stephens Bret M. , Guerrero Paola A. , Huang Yanqing , Zhao Jun , Kamyabi Nabiollah , Sen Subrata , Scheet Paul A. , Taniguchi Cullen M. , Kim Michael P. , Tzeng Ching-Wei , Katz Matthew H. , Singhi Aatur D. , Maitra Anirban , Alvarez Hector A.
Published: April 2023

Correlation heatmap of Pearson correlation coefficients of hierarchically clustered individual cells across stromal populations identified by originating lesion type and tSNE cluster suggests multiple unique subtypes.
Supplementary Data from A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma
Authors: McMichael Elizabeth L. , Benner Brooke , Atwal Lakhvir S. , Courtney Nicholas B. , Mo Xiaokui , Davis Melanie E. , Campbell Amanda R. , Duggan Megan C. , Williams Kallan , Martin Kyle , Levine Kala , Olaverria Salavaggione Gonzalo N. , Noel Tiffany , Ganju Akaansha , Uppati Sarvani , Paul Bonnie , Olencki Thomas , Teknos Theodoros N. , Savvides Panos , Tridandapani Susheela , Byrd John C. , Caligiuri Michael A. , Liu Stephen V. , Carson William E.
Published: April 2023

Supplemental Figure Legends
Figure S4 from lncRNA THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome via Sponging miR-484 and Interacting with YAP
Authors: Li Nan , Yang Guohua , Luo Liyun , Ling Li , Wang Xiaorong , Shi Lejuan , Lan Junsong , Jia Xiaoting , Zhang Qiong , Long Ze , Liu Jinbao , Hu Weimin , He Zhimin , Liu Haiying , Liu Wanqing , Zheng Guopei
Published: April 2023

Figure S4, related to Figure 4. THAP9-AS1 increases YAP expression by sponging miR-484.
Table S5 from Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy
Authors: Hai Josephine , Zhang Hua , Zhou Jin , Wu Zhong , Chen Ting , Papadopoulos Eleni , Dowling Catríona M. , Pyon Val , Pan Yuanwang , Liu Jie Bin , Bronson Roderick T. , Silver Heather , Lizotte Patrick H. , Deng Jiehui , Campbell Joshua D. , Sholl Lynette M. , Ng Christine , Tsao Ming-Sound , Thakurdin Cassandra , Bass Adam J. , Wong Kwok-Kin
Published: April 2023

Pathway enrichment of differentially expressed genes (DEG) between mouse LSCC and LADC.
Supplemental Data from Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model
Authors: Juthani Rupa , Madajewski Brian , Yoo Barney , Zhang Li , Chen Pei-Ming , Chen Feng , Turker Melik Z. , Ma Kai , Overholtzer Michael , Longo Valerie A. , Carlin Sean , Aragon-Sanabria Virginia , Huse Jason , Gonen Mithat , Zanzonico Pat , Rudin Charles M. , Wiesner Ulrich , Bradbury Michelle S. , Brennan Cameron W.
Published: April 2023

Word document including all supplemental figures and text
Table S3 from Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy
Authors: Hai Josephine , Zhang Hua , Zhou Jin , Wu Zhong , Chen Ting , Papadopoulos Eleni , Dowling Catríona M. , Pyon Val , Pan Yuanwang , Liu Jie Bin , Bronson Roderick T. , Silver Heather , Lizotte Patrick H. , Deng Jiehui , Campbell Joshua D. , Sholl Lynette M. , Ng Christine , Tsao Ming-Sound , Thakurdin Cassandra , Bass Adam J. , Wong Kwok-Kin
Published: April 2023

Antibodies used for Immunohistochemistry, Immunofluroesence and immunblotting
Supplementary Tables from Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
Authors: Ribas Antoni , Daud Adil , Pavlick Anna C. , Gonzalez Rene , Lewis Karl D. , Hamid Omid , Gajewski Thomas F. , Puzanov Igor , Wongchenko Matthew , Rooney Isabelle , Hsu Jessie J. , Yan Yibing , Park Erica , McArthur Grant A.
Published: April 2023

Supplementary tables
Table S3 from Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis
Authors: Yoon Harry H. , Shi Qian , Heying Erica N. , Muranyi Andrea , Bredno Joerg , Ough Faith , Djalilvand Azita , Clements June , Bowermaster Rebecca , Liu Wen-Wei , Barnes Michael , Alberts Steven R. , Shanmugam Kandavel , Sinicrope Frank A.
Published: April 2023

Table S3: Association between T-cell subtypes and covariates in MMR-deficient and -proficient stage III colon cancers.
FigureS1 from Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8+ T-Cell–Dependent Tumor Activity
Authors: Watanabe Tsubasa , Gaedicke Simone , Guffart Elena , Firat Elke , Niedermann Gabriele
Published: April 2023

Supplementary Figure 1
Table S5 from Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer
Authors: Flores-Morales Amilcar , Bergmann Tobias B. , Lavallee Charlotte , Batth Tanveer S. , Lin Dong , Lerdrup Mads , Friis Stine , Bartels Anette , Kristensen Gitte , Krzyzanowska Agnieszka , Xue Hui , Fazli Ladan , Hansen Klaus H. , Røder Martin A. , Brasso Klaus , Moreira José M. , Bjartell Anders , Wang Yuzhuo , Olsen Jesper V. , Collins Colin C. , Iglesias-Gato Diego
Published: April 2023

Table S5
Table S1 from Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer
Authors: Flores-Morales Amilcar , Bergmann Tobias B. , Lavallee Charlotte , Batth Tanveer S. , Lin Dong , Lerdrup Mads , Friis Stine , Bartels Anette , Kristensen Gitte , Krzyzanowska Agnieszka , Xue Hui , Fazli Ladan , Hansen Klaus H. , Røder Martin A. , Brasso Klaus , Moreira José M. , Bjartell Anders , Wang Yuzhuo , Olsen Jesper V. , Collins Colin C. , Iglesias-Gato Diego
Published: April 2023

Table S1
Figure S1 from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
Authors: Steenbruggen Tessa G. , van Seijen Maartje , Janssen Liselore M. , van Ramshorst Mette S. , van Werkhoven Erik , Vrancken Peeters Marie-Jeanne T.D.F. , Wesseling Jelle , Lips Esther H. , Sonke Gabe S.
Published: April 2023

Figure S1 from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
Supplementary Data from Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study
Authors: Wang Zhixiong , Kambhampati Swetha , Cheng Yulan , Ma Ke , Simsek Cem , Tieu Alan H. , Abraham John M. , Liu Xi , Prasath Vishnu , Duncan Mark , Stark Alejandro , Trick Alexander , Tsai Hua-Ling , Wang Hao , He Yulong , Khashab Mouen A. , Ngamruengphong Saowanee , Shin Eun J. , Wang Tza-Huei , Meltzer Stephen J.
Published: April 2023

supplementary figures and tables
Supplementary Table 3 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Authors: Keung Emily Z. , Burgess Melissa , Salazar Ruth , Parra Edwin R. , Rodrigues-Canales Jaime , Bolejack Vanessa , Van Tine Brian A. , Schuetze Scott M. , Attia Steven , Riedel Richard F. , Hu James , Okuno Scott H. , Priebat Dennis A. , Movva Sujana , Davis Lara E. , Reed Damon R. , Reuben Alexandre , Roland Christina L. , Reinke Denise , Lazar Alexander J. , Wang Wei-Lien , Wargo Jennifer A. , Tawbi Hussein A.
Published: April 2023

Comparison of tumor PD-L1 expression and tumor immune infiltrate between baseline tumor biopsies from responders and nonresponders (STS only)
Supplemental Figure S2 from Smoothened Promotes Glioblastoma Radiation Resistance Via Activating USP3-Mediated Claspin Deubiquitination
Authors: Tu Yiming , Chen Zhenyao , Zhao Pengzhan , Sun Guangchi , Bao Zhongyuan , Chao Honglu , Fan Liang , Li Chong , You Yongping , Qu Yan , Chen Yun , Ji Jing
Published: April 2023

Supplemental Figure S2
Supplemental Figure S11 from Smoothened Promotes Glioblastoma Radiation Resistance Via Activating USP3-Mediated Claspin Deubiquitination
Authors: Tu Yiming , Chen Zhenyao , Zhao Pengzhan , Sun Guangchi , Bao Zhongyuan , Chao Honglu , Fan Liang , Li Chong , You Yongping , Qu Yan , Chen Yun , Ji Jing
Published: April 2023

Supplemental Figure S11
Supplementary Figure 1 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Authors: Keung Emily Z. , Burgess Melissa , Salazar Ruth , Parra Edwin R. , Rodrigues-Canales Jaime , Bolejack Vanessa , Van Tine Brian A. , Schuetze Scott M. , Attia Steven , Riedel Richard F. , Hu James , Okuno Scott H. , Priebat Dennis A. , Movva Sujana , Davis Lara E. , Reed Damon R. , Reuben Alexandre , Roland Christina L. , Reinke Denise , Lazar Alexander J. , Wang Wei-Lien , Wargo Jennifer A. , Tawbi Hussein A.
Published: April 2023

Response to anti-PD1 therapy is associated with higher levels of PD-L1 expression by (A) tumor cells and (B) tumor infiltrating macrophages and higher density of sarcoma-associated immune infiltrates at baseline. Tumor biopsies obtained from patients who responded to pembrolizumab therapy had higher baseline density (cell count/mm2) of tumor infiltrating (C) T lymphocytes, (D) cytotoxic T lymphocytes, (E) antigen experience T lymphocytes, (F) antigen experienced cytotoxic T lymphocytes, (G) activated cytotoxic T lymphocytes, (H) effector memory cytotoxic T lymphocytes, and (I) regulatory T lymphocytes. Baseline tumor samples available for immune profiling by IHC were obtained prior to anti-PD1 treatment (8 responder and 58 non-responder patients). Error bars represent SEM. * = p{less than or equal to}0.05, ** = p{less than or equal to}0.01, *** = p{less than or equal to}0.001, n.s. = not significant.
Supplementary Data from Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia
Authors: Hao Mu , Barlogie Bart , Tricot Guido , Liu Lanting , Qiu Lugui , Shaughnessy John D. , Zhan Fenghuang
Published: April 2023

Supplemental Data: four Tables and one Figure Supplement Table 1. B-cell markers and differentiation-related genes in WM, MM, and their normal counterparts Supplement Table 2. Most differentially expressed genes (n = 55) allowing the distinction of WM-BC from PB-BC and T-BC Supplement Table 3. Most differentially expressed genes (n = 46) allowing the distinction of WM-PC from T-PC and N-PC Supplemental Table 4. Clinical information of WM patients used for the Figure 4 Supplemental Fig. 1: Immunofluorescence shows CD3 expression (Green) on normal T cells and CD19 expression (Red) on normal B cells derived from peripheral blood of a healthy donor. DAPI (blue color) was used to stain cell nuclei.
Supplementary Video S2 from Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models
Authors: Zhang Mo , Kobayashi Naoko , Zettlitz Kirstin A. , Kono Evelyn A. , Yamashiro Joyce M. , Tsai Wen-Ting K. , Jiang Ziyue K. , Tran Chau P. , Wang Chung , Guan Johnny , Wu Anna M. , Reiter Robert E.
Published: April 2023

Resection surgery of lymph node metastasis of PC3-PSCA-fluc tumor with fluorescence navigation by A11 Mb-IRDye800CW
Figure S1 from Human Breast Cancer Xenograft Model Implicates Peroxisome Proliferator–activated Receptor Signaling as Driver of Cancer-induced Muscle Fatigue
Authors: Wilson Hannah E. , Rhodes Kacey K. , Rodriguez Daniel , Chahal Ikttesh , Stanton David A. , Bohlen Joseph , Davis Mary , Infante Aniello M. , Hazard-Jenkins Hannah , Klinke David J. , Pugacheva Elena N. , Pistilli Emidio E.
Published: April 2023

Figure S1 shows additional data from Enrichr in silico analyses, and protein analyses of STAT 3 and STAT5.
Figure S7 from Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
Authors: Max Ma Xiaoju , Bendell Johanna C. , Hurwitz Herbert I. , Ju Christine , Lee John J. , Lovejoy Alex , Mancao Christoph , Nicholas Alan , Price Richard , Sommer Nicolas , Tikoo Nalin , Yao Lijing , Yaung Stephanie J. , Palma John F.
Published: April 2023

Supplementary Figure
Supplementary Data from The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Authors: Knepper Todd C. , Montesion Meagan , Russell Jeffery S. , Sokol Ethan S. , Frampton Garrett M. , Miller Vincent A. , Albacker Lee A. , McLeod Howard L. , Eroglu Zeynep , Khushalani Nikhil I. , Sondak Vernon K. , Messina Jane L. , Schell Michael J. , DeCaprio James A. , Tsai Kenneth Y. , Brohl Andrew S.
Published: April 2023

Figure S3
Figure S13 from Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
Authors: Max Ma Xiaoju , Bendell Johanna C. , Hurwitz Herbert I. , Ju Christine , Lee John J. , Lovejoy Alex , Mancao Christoph , Nicholas Alan , Price Richard , Sommer Nicolas , Tikoo Nalin , Yao Lijing , Yaung Stephanie J. , Palma John F.
Published: April 2023

Supplementary Figure
Supplementary Table 3 from Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma
Authors: Tan Yinfei , Sementino Eleonora , Cheung Mitchell , Peri Suraj , Menges Craig W. , Kukuyan Anna-Mariya , Zhang Ting , Khazak Vladimir , Fox Lauren A. , Ross Eric A. , Ramanathan Suresh , Jhanwar Suresh C. , Flores Raja M. , Balachandran Siddharth , Testa Joseph R.
Published: April 2023

Lentivirus plasmids expressing shMLKL.
Supplementary Figure S3 from Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study
Authors: Buus Richard , Sestak Ivana , Barron Stephen , Loughman Tony , Fender Bozena , Ruiz Cesar Lopez , Dynoodt Peter , Wang Chan-Ju Angel , O'Leary Des , Gallagher William M. , Dowsett Mitch , Cuzick Jack
Published: April 2023

Kaplan-Meier plots for 10 year distant recurrence for CTS and CTS+OMclin2 composite continuous score split by the score median in node-negative and node-positive patients, respectively. *Due to the distribution of CTS score, dividing the cohort by the score median resulted in slightly uneven groups. The numbers of patients at risk in each group at various time points are given below each graph. CTS, clinical treatment score; med, median; CI, confidence interval
Supplementary Figure 9B from Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma
Authors: Tan Yinfei , Sementino Eleonora , Cheung Mitchell , Peri Suraj , Menges Craig W. , Kukuyan Anna-Mariya , Zhang Ting , Khazak Vladimir , Fox Lauren A. , Ross Eric A. , Ramanathan Suresh , Jhanwar Suresh C. , Flores Raja M. , Balachandran Siddharth , Testa Joseph R.
Published: April 2023

Drug sensitivity differences between 12 RIPK3-negative and 3 RIPK3-positive human MM cell lines as assessed by MTS assay. Treatment of MM cell lines with three different doses of doxorubicin. First three bars in each bar graph represent viability of RIPK3-positive (+) MM cell lines, M49, M29 and M217, respectively. The bars shown to the right in each graph represent the viability of each of the 12 RIPK3-negative (-) MM lines. All drug treatments were for 72 h.
Figure S4 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
Authors: Henderson Meredith C. , Silver Michael , Tran Quynh , Letsios Elias E. , Mulpuri Rao , Reese David E. , Lourenco Ana P. , LaBaer Joshua , Anderson Karen S. , Alpers Josie , Costantini Carrie , Rohatgi Nitin , Ali Haythem , Baker Karen , Northfelt Donald W. , Ghosh Karthik , Grobmyer Stephen R. , Polen Winnie , Wolf Judith K.
Published: April 2023

Figure S4: ROC overlay demonstrating relationship between FSH values and menopause status. Separate curves were generated for pre (n=333) vs. post (n=317) and vs. post/peri (n=390). Subjects who had undergone hysterectomy were excluded in these analyses.
Supplementary Figure 7A, B from Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma
Authors: Tan Yinfei , Sementino Eleonora , Cheung Mitchell , Peri Suraj , Menges Craig W. , Kukuyan Anna-Mariya , Zhang Ting , Khazak Vladimir , Fox Lauren A. , Ross Eric A. , Ramanathan Suresh , Jhanwar Suresh C. , Flores Raja M. , Balachandran Siddharth , Testa Joseph R.
Published: April 2023

Re-expression of RIPK3 expression triggers necroptosis in RIPK3-negative MM cell lines, and RIPK3 inhibition rescues the cell death caused by necroptosis. A, RIPK3-negative MM cell lines M12 and M22 were transduced with WPI lentivirus expressing RIPK3 WT or empty vector and treated with the apoptosis inhibitor zVAD and/or the RIPK3 inhibitor GSK'872 for 1-4 d. Results of immunoblot analysis (24 h) and clonogenic assay (4 d) are shown. B, Cell viability determined with hemocytometer and trypan blue dye exclusion test.
Supplementary Figure 1C from Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma
Authors: Tan Yinfei , Sementino Eleonora , Cheung Mitchell , Peri Suraj , Menges Craig W. , Kukuyan Anna-Mariya , Zhang Ting , Khazak Vladimir , Fox Lauren A. , Ross Eric A. , Ramanathan Suresh , Jhanwar Suresh C. , Flores Raja M. , Balachandran Siddharth , Testa Joseph R.
Published: April 2023

Immunoblot analysis demonstrating re-expression of wild type (WT) or kinase dead (KD) RIPK3 in four RIPK3-negative human MM cell lines after infection with lentivirus for 24 h. MM cell lines were infected with pWPI lentivirus that expresses GFP alone or with pWPI lentivirus that expresses both GFP and either RIPK3 WT or RIPK3-KD.
Table S7 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Authors: Chakraborty Goutam , Armenia Joshua , Mazzu Ying Z. , Nandakumar Subhiksha , Stopsack Konrad H. , Atiq Mohammad O. , Komura Kazumasa , Jehane Lina , Hirani Rahim , Chadalavada Kalyani , Yoshikawa Yuki , Khan Nabeela A. , Chen Yu , Abida Wassim , Mucci Lorelei A. , Lee Gwo-Shu Mary , Nanjangud Gouri J. , Kantoff Philip W.
Published: April 2023

Supplementary Table S7
Figure S5 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Authors: Chakraborty Goutam , Armenia Joshua , Mazzu Ying Z. , Nandakumar Subhiksha , Stopsack Konrad H. , Atiq Mohammad O. , Komura Kazumasa , Jehane Lina , Hirani Rahim , Chadalavada Kalyani , Yoshikawa Yuki , Khan Nabeela A. , Chen Yu , Abida Wassim , Mucci Lorelei A. , Lee Gwo-Shu Mary , Nanjangud Gouri J. , Kantoff Philip W.
Published: April 2023

Supplementary Figure S5
Figure S4 from Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Authors: Recondo Gonzalo , Mezquita Laura , Facchinetti Francesco , Planchard David , Gazzah Anas , Bigot Ludovic , Rizvi Ahsan Z. , Frias Rosa L. , Thiery Jean Paul , Scoazec Jean-Yves , Sourisseau Tony , Howarth Karen , Deas Olivier , Samofalova Dariia , Galissant Justine , Tesson Pauline , Braye Floriane , Naltet Charles , Lavaud Pernelle , Mahjoubi Linda , Abou Lovergne Aurélie , Vassal Gilles , Bahleda Rastilav , Hollebecque Antoine , Nicotra Claudio , Ngo-Camus Maud , Michiels Stefan , Lacroix Ludovic , Richon Catherine , Auger Nathalie , De Baere Thierry , Tselikas Lambros , Solary Eric , Angevin Eric , Eggermont Alexander M. , Andre Fabrice , Massard Christophe , Olaussen Ken A. , Soria Jean-Charles , Besse Benjamin , Friboulet Luc
Published: April 2023

Supplementary Figure 4: NF2 inhibition of mTORC1 and its canonical pathway.
Supplementary Data from ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma
Authors: Calderaro Julien , Meunier Léa , Nguyen Cong Trung , Boubaya Marouane , Caruso Stefano , Luciani Alain , Amaddeo Giuliana , Regnault Hélène , Nault Jean-Charles , Cohen Justine , Oberti Frédéric , Michalak Sophie , Bouattour Mohamed , Vilgrain Valérie , Pageaux Georges Philippe , Ramos Jeanne , Barget Nathalie , Guiu Boris , Paradis Valérie , Aubé Christophe , Laurent Alexis , Pawlotsky Jean-Michel , Ganne-Carrié Nathalie , Zucman-Rossi Jessica , Seror Olivier , Ziol Marianne
Published: April 2023

Supplemental Data
Supplementary Methods from Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma
Authors: Indraccolo Stefano , Lombardi Giuseppe , Fassan Matteo , Pasqualini Lorenza , Giunco Silvia , Marcato Raffaella , Gasparini Alessandra , Candiotto Cinzia , Nalio Silvia , Fiduccia Pasquale , Fanelli Giuseppe Nicolò , Pambuku Ardi , Della Puppa Alessandro , D'Avella Domenico , Bonaldi Laura , Gardiman Marina Paola , Bertorelle Roberta , De Rossi Anita , Zagonel Vittorina
Published: April 2023

Suppl. Methods: Sanger sequencing, IDH1/2 mutations and Fluorescence in situ hybridization (FISH)
Figure S8 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Authors: Ritch Elie , Fu Simon Y.F. , Herberts Cameron , Wang Gang , Warner Evan W. , Schönlau Elena , Taavitsainen Sinja , Murtha Andrew J. , Vandekerkhove Gillian , Beja Kevin , Loktionova Yulia , Khalaf Daniel , Fazli Ladan , Kushnir Igal , Ferrario Cristiano , Hotte Sebastien , Annala Matti , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure 8. Heterogeneity in TP53 variant allele frequency in MMRd patients.
Figure S5 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Authors: Ritch Elie , Fu Simon Y.F. , Herberts Cameron , Wang Gang , Warner Evan W. , Schönlau Elena , Taavitsainen Sinja , Murtha Andrew J. , Vandekerkhove Gillian , Beja Kevin , Loktionova Yulia , Khalaf Daniel , Fazli Ladan , Kushnir Igal , Ferrario Cristiano , Hotte Sebastien , Annala Matti , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure 5. Somatic mutation trinucleotide contexts.
Figure S2 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Authors: Ritch Elie , Fu Simon Y.F. , Herberts Cameron , Wang Gang , Warner Evan W. , Schönlau Elena , Taavitsainen Sinja , Murtha Andrew J. , Vandekerkhove Gillian , Beja Kevin , Loktionova Yulia , Khalaf Daniel , Fazli Ladan , Kushnir Igal , Ferrario Cristiano , Hotte Sebastien , Annala Matti , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure 2. Mutations in selected genes.
Supplementary Table 1 from Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion
Authors: Ryu Daeun , Kim Seok Jin , Hong Yourae , Jo Areum , Kim Nayoung , Kim Hee-Jin , Lee Hae-Ock , Kim Kihyun , Park Woong-Yang
Published: April 2023

. Immune cell type identification using DEGs and annotation package SingleR.
Supplementary Legend from Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion
Authors: Ryu Daeun , Kim Seok Jin , Hong Yourae , Jo Areum , Kim Nayoung , Kim Hee-Jin , Lee Hae-Ock , Kim Kihyun , Park Woong-Yang
Published: April 2023

Supplementary Legend
Move S1 from Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography
Authors: Greenwood Hannah E. , McCormick Patrick N. , Gendron Thibault , Glaser Matthias , Pereira Raul , Maddocks Oliver D. K. , Sander Kerstin , Zhang Tong , Koglin Norman , Lythgoe Mark F. , Årstad Erik , Hochhauser Daniel , Witney Timothy H.
Published: April 2023

Video 1
Supplementary Data from YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer
Authors: Li Fan , Xu Yan , Liu Bovey , Singh Pankaj Kumar , Zhao Wei , Jin Jiankang , Han Guangchun , Scott Ailing W. , Dong Xiaochuan , Huo Longfei , Ma Lang , Pizzi Melissa Pool , Wang Ying , Li Yuan , Harada Kazuto , Xie Min , Skinner Heath D. , Ding Sheng , Wang Linghua , Krishnan Sunil , Johnson Randy L. , Song Shumei , Ajani Jaffer A.
Published: April 2023

Supplemental Figure 1-4 Legends
Supplementary Figure 4 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Authors: Yan Dongqing , Pomicter Anthony D. , Tantravahi Srinivas , Mason Clinton C. , Senina Anna V. , Ahmann Jonathan M. , Wang Qiang , Than Hein , Patel Ami B. , Heaton William L. , Eiring Anna M. , Clair Phillip M. , Gantz Kevin C. , Redwine Hannah M. , Swierczek Sabina I. , Halverson Brayden J. , Baloglu Erkan , Shacham Sharon , Khorashad Jamshid S. , Kelley Todd W. , Salama Mohamed E. , Miles Rodney R. , Boucher Kenneth M. , Prchal Josef T. , O'Hare Thomas , Deininger Michael W.
Published: April 2023

Supplementary Figure 4
Supplementary Data from A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features
Authors: Sarkozy Clémentine , Morschhauser Franck , Dubois Sydney , Molina Thierry , Michot Jean Marie , Cullières-Dartigues Peggy , Suttle Benjamin , Karlin Lionel , Le Gouill Steven , Picquenot Jean-Michel , Dubois Romain , Tilly Hervé , Herbaux Charles , Jardin Fabrice , Salles Gilles , Ribrag Vincent
Published: April 2023

- Supplementary table 1: incidence of Grade 3-5 hematologic toxicities with Epi-R-CHOP compared to recent R-CHOP trial and other R-CHOP / novel agent combinations. - Supplementary table 2: metabolic CR rate for the recent R-CHOP and R-CHOP combination studies. - Supplementary figure 1: Pharmacokinetic analysis - Supplementary figure 2: mutation frequencies for the 15 evaluable cases
Supplementary Data from Oncolytic HSV–Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition
Authors: Otani Yoshihiro , Yoo Ji Young , Chao Samantha , Liu Joseph , Jaime-Ramirez Alena Cristina , Lee Tae Jin , Hurwitz Brian , Yan Yuanqing , Dai Hongsheng , Glorioso Joseph C. , Caligiuri Michael A. , Yu Jianhua , Kaur Balveen
Published: April 2023

Supplementary Table
Supplementary figure 2 from Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity
Authors: Baro Marta , Lopez Sambrooks Cecilia , Quijano Amanda , Saltzman W. Mark , Contessa Joseph
Published: April 2023

Time course resolution of γH2AX foci formation in D54 cells
Supplemental Table 1 from Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma
Authors: Amin Jay , Xu Bo , Badkhshan Shervin , Creighton Terrance T. , Abbotoy Daniel , Murekeyisoni Christine , Attwood Kristopher M. , Schwaab Thomas , Hendler Craig , Petroziello Michael , Roche Charles L. , Kauffman Eric C.
Published: April 2023

Eosinophilia in ChRCC tumors
Supplemental Figure 3 from Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma
Authors: Amin Jay , Xu Bo , Badkhshan Shervin , Creighton Terrance T. , Abbotoy Daniel , Murekeyisoni Christine , Attwood Kristopher M. , Schwaab Thomas , Hendler Craig , Petroziello Michael , Roche Charles L. , Kauffman Eric C.
Published: April 2023

Representative examples of CD117 and CK immunostaining in ChRCC and RO tumors. Representative staining images are shown at 100X magnification. (A-B) Hematoxylin & Eosin staining for (A) ChRCC and (B) RO. (C-D) Typical strong/diffuse CD117 staining in (C) ChRCC and (D) RO. (E-F) Atypical focal/weak CD117 staining in (E) ChRCC and (F) RO. (G-H) Typical CK7 staining that is (G) strong/diffuse in ChRCC and (H) negative in RO. (I-J) Atypical CK7 staining that is (I) focal/weak in ChRCC and (J) strong/diffuse in RO.
Legends supplementary Figures 1-6 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Authors: Toledo Rodrigo A. , Garralda Elena , Mitsi Maria , Pons Tirso , Monsech Jorge , Vega Estela , Otero Álvaro , Albarran Maria I. , Baños Natalia , Durán Yolanda , Bonilla Victoria , Sarno Francesca , Camacho-Artacho Marta , Sanchez-Perez Tania , Perea Sofia , Álvarez Rafael , De Martino Alba , Lietha Daniel , Blanco-Aparicio Carmen , Cubillo Antonio , Domínguez Orlando , Martínez-Torrecuadrada Jorge L. , Hidalgo Manuel
Published: April 2023

Legends for Supplementary Figures 1-6
Supplemental Figure 2 from Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma
Authors: Amin Jay , Xu Bo , Badkhshan Shervin , Creighton Terrance T. , Abbotoy Daniel , Murekeyisoni Christine , Attwood Kristopher M. , Schwaab Thomas , Hendler Craig , Petroziello Michael , Roche Charles L. , Kauffman Eric C.
Published: April 2023

Representative CT imaging of CD117(-) RO/ChRCC tumors using an early contrast phase. (A) This representative CD117(-) RO tumor has relative hyperenhancement (tumor:cortex PEER 0.79) that is similar to CD117(+) RO tumors; (B) Thisrepresentative CD117(-) ChRCC tumor has relative hyperenhancement (tumor:cortex PEER 0.76) that is similar to RO tumors and in contrast to CD117(+) ChRCC tumors.
Figure S4 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Authors: Toledo Rodrigo A. , Garralda Elena , Mitsi Maria , Pons Tirso , Monsech Jorge , Vega Estela , Otero Álvaro , Albarran Maria I. , Baños Natalia , Durán Yolanda , Bonilla Victoria , Sarno Francesca , Camacho-Artacho Marta , Sanchez-Perez Tania , Perea Sofia , Álvarez Rafael , De Martino Alba , Lietha Daniel , Blanco-Aparicio Carmen , Cubillo Antonio , Domínguez Orlando , Martínez-Torrecuadrada Jorge L. , Hidalgo Manuel
Published: April 2023

Figure S4: A) Molecular dynamics simulations with L840F VEGFR2 indicates that most of the adopted F840 conformations during the simulation are not compatible with inhibitor binding. Clashes between VEGFR2 and the sorafenib area are shown as red discs. B) Kinase assays showing impaired kinase activities of VEGFR2 L840F and R1032Q compared to wild-type. C) Effects of the L840F mutation on Y1175 VEGFR2 phosphorylation. HEK293 cells were transiently transfected with increasing levels of a plasmid encoding for WT or L840F VEGFR2. Cells at 70% confluence were starved in 1% BSA/DMEM for 4 h, and then incubated in the absence or presence of 60 ng/ml VEGF165 for 10 min at 37 {degree sign}C. Whole cell lysates were analyzed by western blotting, using antibodies against phosphoY1175 and total VEGFR2. Representative results are shown. D) PAE cells stably expressing WT or L840F VEGFR2 were generated from a PAE cell line that does not normally express VEGFR2 (empty). Cells at 70% confluence were starved in 1% BSA/DMEM for 4h, and then incubated in the absence or presence of 60 ng/ml VEGF165 for 10 min at 37 {degree sign}C. Whole cell lysates were then analyzed by western blotting, using antibodies against phosphoY1175 and total VEGFR2. Representative results are shown, highlighting the significant decrease in VEGF-induced Y1175 VEGFR2 phosphorylation in the presence of the L840F mutation.
Figure S1 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Authors: Toledo Rodrigo A. , Garralda Elena , Mitsi Maria , Pons Tirso , Monsech Jorge , Vega Estela , Otero Álvaro , Albarran Maria I. , Baños Natalia , Durán Yolanda , Bonilla Victoria , Sarno Francesca , Camacho-Artacho Marta , Sanchez-Perez Tania , Perea Sofia , Álvarez Rafael , De Martino Alba , Lietha Daniel , Blanco-Aparicio Carmen , Cubillo Antonio , Domínguez Orlando , Martínez-Torrecuadrada Jorge L. , Hidalgo Manuel
Published: April 2023

Figure S1: Read alignments from WES-cfDNA, showing somatic mutations in APC and TP53 genes.
Supplementary Data from The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study
Authors: Stamatopoulos Basile , Smith Thomas , Crompot Emerence , Pieters Karlien , Clifford Ruth , Mraz Marek , Robbe Pauline , Burns Adam , Timbs Adele , Bruce David , Hillmen Peter , Meuleman Nathalie , Mineur Philippe , Firescu Radu , Maerevoet Marie , De Wilde Virginie , Efira André , Philippé Jan , Verhasselt Bruno , Offner Fritz , Sims David , Heger Andreas , Dreau Hélène , Schuh Anna
Published: April 2023

Supplementary Data Figure S1. Determination of IgLV3-21 positivity by real-time PCR. Supplementary Data Figure S2: CLL-OS analysis including only CLL-related deaths. Supplementary Data Figure S3. Validation of the poor prognosis associated with IgLV3-21 usage in population C. Supplementary Data Figure S4. Validation of the poor prognosis of IgLV3-21 usage in population D. Supplementary Data Figure S5: prognostic impact of IgLV3-21 usage in the different CLL-IPI subgroups. Supplementary Data Figure S6. Immunogenetic features of IgLV3-21 patients. Supplementary Data Figure S7. CXCR4 surface expression is downregulated in IgLV3-21 patients.
Supplementary Figures from Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness
Authors: Molina-Crespo Ángela , Cadete Ana , Sarrio David , Gámez-Chiachio Manuel , Martinez Lidia , Chao Kinlin , Olivera Ana , Gonella Andrea , Díaz Eva , Palacios José , Dhal Pradeep K. , Besev Magnus , Rodríguez-Serrano Macarena , García Bermejo María Laura , Triviño Juan Carlos , Cano Amparo , García-Fuentes Marcos , Herzberg Osnat , Torres Dolores , Alonso Maria José , Moreno-Bueno Gema
Published: April 2023

Supplementary Figures S1-S10
Supplementary Data Tables from The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study
Authors: Stamatopoulos Basile , Smith Thomas , Crompot Emerence , Pieters Karlien , Clifford Ruth , Mraz Marek , Robbe Pauline , Burns Adam , Timbs Adele , Bruce David , Hillmen Peter , Meuleman Nathalie , Mineur Philippe , Firescu Radu , Maerevoet Marie , De Wilde Virginie , Efira André , Philippé Jan , Verhasselt Bruno , Offner Fritz , Sims David , Heger Andreas , Dreau Hélène , Schuh Anna
Published: April 2023

Supplementary Data Table S1: general characterisctic of the different cohorts of patients Supplementary Data Table S2: characterisctic of Population A Supplementary Data Table S3: characterisctic of Population B Supplementary Data Table S4: characterisctic of Population C Supplementary Data Table S5: characterisctic of Population D Supplementary Data Table S6: Primer sequences Supplementary Data Table S7: Differentially expressed transcripts between IgLV3-21 + and - patients Supplementary Data Table S8: differentially expressed genes between IgLV3-21 + and - patients Supplementary Data Table S9: differentially expressed genes between IgLV3-21 + and - patients. Restricted to absolute fold-change > 1.5 and protein coding genes only Supplementary Data Table S10 Gene set Enrichment analysis between IgLV3-21 positive and negative patients
Supplementary Table 1 from Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors
Authors: Atrafi Florence , van Eerden Ruben A.G. , van Hylckama Vlieg Marte A.M , Oomen-de Hoop Esther , de Bruijn Peter , Lolkema Martijn P. , Moelker Adriaan , Rijcken Cristianne J. , Hanssen Rob , Sparreboom Alex , Eskens Ferry A.L.M. , Mathijssen Ron H.J. , Koolen Stijn L.W.
Published: April 2023

Supplementary Table 1 clean version
Supplementary Data from Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma
Authors: Cao Jianbo , Pickup Stephen , Clendenin Cynthia , Blouw Barbara , Choi Hoon , Kang David , Rosen Mark , O'Dwyer Peter J. , Zhou Rong
Published: April 2023

Supplementary figures 1-3
Supplementary Data from A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Authors: Patel Sandip P. , Othus Megan , Chae Young Kwang , Giles Francis J. , Hansel Donna E. , Singh Preet Paul , Fontaine Annette , Shah Manisha H. , Kasi Anup , Baghdadi Tareq Al , Matrana Marc , Gatalica Zoran , Korn W. Michael , Hayward Jourdain , McLeod Christine , Chen Helen X. , Sharon Elad , Mayerson Edward , Ryan Christopher W. , Plets Melissa , Blanke Charles D. , Kurzrock Razelle
Published: April 2023

Appendix
Table S4 from Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
Authors: Amin-Mansour Ali , George Suzanne , Sioletic Stefano , Carter Scott L. , Rosenberg Mara , Taylor-Weiner Amaro , Stewart Chip , Chevalier Aaron , Seepo Sara , Tracy Adam , Getz Gad , Hornick Jason L. , Nucci Marisa R. , Quade Bradley , Demetri George D. , Raut Chandrajit P. , Garraway Levi A. , Van Allen Eliezer M. , Wagner Andrew J.
Published: April 2023

Supplementary Table 4
Table S1 from Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
Authors: Amin-Mansour Ali , George Suzanne , Sioletic Stefano , Carter Scott L. , Rosenberg Mara , Taylor-Weiner Amaro , Stewart Chip , Chevalier Aaron , Seepo Sara , Tracy Adam , Getz Gad , Hornick Jason L. , Nucci Marisa R. , Quade Bradley , Demetri George D. , Raut Chandrajit P. , Garraway Levi A. , Van Allen Eliezer M. , Wagner Andrew J.
Published: April 2023

Supplementary Table 1
Table S7 from Characterization of Alternative Splicing Events in HPV-Negative Head and Neck Squamous Cell Carcinoma Identifies an Oncogenic DOCK5 Variant
Authors: Liu Chao , Guo Theresa , Xu Guorong , Sakai Akihiro , Ren Shuling , Fukusumi Takahito , Ando Mizuo , Sadat Sayed , Saito Yuki , Khan Zubair , Fisch Kathleen M. , Califano Joseph
Published: April 2023

List of differentially expressed genes between patients with higher and lower expression of DOCK5 variant in TCGA HPV negative HNSCC data
Supplementary Figure 3 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer
Authors: Kandimalla Raju , Gao Feng , Matsuyama Takatoshi , Ishikawa Toshiaki , Uetake Hiroyuki , Takahashi Naoki , Yamada Yasuhide , Becerra Carlos , Kopetz Scott , Wang Xin , Goel Ajay
Published: April 2023

Supplementary Figure 3: The MRC significantly predicted recurrence-free interval regardless of the adjuvant chemotherapy treatment. The Kaplan Meier plots from: A, B, C and D) untreated patients; E, F, G and H) patients treated with 5-FU; A, B, E and F) from the fresh-frozen specimens in cohort-1; and C, D, G and H) from the FFPE specimens in cohorts 2 and 3.
Table S5 from Characterization of Alternative Splicing Events in HPV-Negative Head and Neck Squamous Cell Carcinoma Identifies an Oncogenic DOCK5 Variant
Authors: Liu Chao , Guo Theresa , Xu Guorong , Sakai Akihiro , Ren Shuling , Fukusumi Takahito , Ando Mizuo , Sadat Sayed , Saito Yuki , Khan Zubair , Fisch Kathleen M. , Califano Joseph
Published: April 2023

List of junctions in both HPV negative and positive HNSCC
Table S4 from Characterization of Alternative Splicing Events in HPV-Negative Head and Neck Squamous Cell Carcinoma Identifies an Oncogenic DOCK5 Variant
Authors: Liu Chao , Guo Theresa , Xu Guorong , Sakai Akihiro , Ren Shuling , Fukusumi Takahito , Ando Mizuo , Sadat Sayed , Saito Yuki , Khan Zubair , Fisch Kathleen M. , Califano Joseph
Published: April 2023

Correlations between number of ASEs and clinicopathological parameters in TCGA HPV negative HNSCC data
Table S2 from Characterization of Alternative Splicing Events in HPV-Negative Head and Neck Squamous Cell Carcinoma Identifies an Oncogenic DOCK5 Variant
Authors: Liu Chao , Guo Theresa , Xu Guorong , Sakai Akihiro , Ren Shuling , Fukusumi Takahito , Ando Mizuo , Sadat Sayed , Saito Yuki , Khan Zubair , Fisch Kathleen M. , Califano Joseph
Published: April 2023

Full list of 580 validated ASEs associated with HPV negative HNSCC
Table S1 from Characterization of Alternative Splicing Events in HPV-Negative Head and Neck Squamous Cell Carcinoma Identifies an Oncogenic DOCK5 Variant
Authors: Liu Chao , Guo Theresa , Xu Guorong , Sakai Akihiro , Ren Shuling , Fukusumi Takahito , Ando Mizuo , Sadat Sayed , Saito Yuki , Khan Zubair , Fisch Kathleen M. , Califano Joseph
Published: April 2023

Primer and siRNA sequences of DOCK5 wide-type and variant
Table S1 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Authors: Nava Rodrigues Daniel , Casiraghi Nicola , Romanel Alessandro , Crespo Mateus , Miranda Susana , Rescigno Pasquale , Figueiredo Ines , Riisnaes Ruth , Carreira Suzanne , Sumanasuriya Semini , Gasperini Paola , Sharp Adam , Mateo Joaquin , Makay Alan , McNair Christopher , Schiewer Matthew , Knudsen Karen , Boysen Gunther , Demichelis Francesca , de Bono Johann S.
Published: April 2023

Table S1
Figure S3 from Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma
Authors: Mohme Malte , Maire Cecile L. , Geumann Ulf , Schliffke Simon , Dührsen Lasse , Fita Krystian , Akyüz Nuray , Binder Mascha , Westphal Manfred , Guenther Christine , Lamszus Katrin , Hermann Felix G. , Schmidt Nils Ole
Published: April 2023

Suppl. Fig. 3. Flow cytometry analysis of T-cell surface marker expression
Figure S2 from Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma
Authors: Mohme Malte , Maire Cecile L. , Geumann Ulf , Schliffke Simon , Dührsen Lasse , Fita Krystian , Akyüz Nuray , Binder Mascha , Westphal Manfred , Guenther Christine , Lamszus Katrin , Hermann Felix G. , Schmidt Nils Ole
Published: April 2023

Suppl. Fig. 2. Cytokine production by MSCs and PBMCs during co-culture and toxicity screening
Supplementary Figure S5 from The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Authors: Pilla Reddy Venkatesh , Anjum Rana , Grondine Michael , Smith Aaron , Bhavsar Deepa , Barry Evan , Guichard Sylvie M. , Shao Wenlin , Kettle Jason G. , Brown Crystal , Banks Erica , Jones Rhys D.O.
Published: April 2023

Fraction Absorbed (Fabs) as a Function of AZD3229 Dose using GI-SIM tool
Figure S1, Figure S2, Table S1 from Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib
Authors: Carneiro Benedito A. , Pamarthy Sahithi , Shah Ami N. , Sagar Vinay , Unno Kenji , Han HuiYing , Yang Ximing J. , Costa Rubens B. , Nagy Rebecca J. , Lanman Richard B. , Kuzel Timothy M. , Ross Jeffrey S. , Gay Laurie , Elvin Julia A. , Ali Siraj M. , Cristofanilli Massimo , Chae Young K. , Giles Francis J. , Abdulkadir Sarki A.
Published: April 2023

Figure S1 ALK genomic alterations and mRNA expression in human cancers. Figure S2 Efficacy of ALK inhibitors in prostate cancer cell lines. Table S1 Summary of mutations and their percentages identified by ctDNA profiling.
Supplementary Figure S3 from The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Authors: Pilla Reddy Venkatesh , Anjum Rana , Grondine Michael , Smith Aaron , Bhavsar Deepa , Barry Evan , Guichard Sylvie M. , Shao Wenlin , Kettle Jason G. , Brown Crystal , Banks Erica , Jones Rhys D.O.
Published: April 2023

Goodness of fit plots of PK/PD model fit for AZD3229
Table S3 from Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation
Authors: Liu Chao , Sadat Sayed H. , Ebisumoto Koji , Sakai Akihiro , Panuganti Bharat A. , Ren Shuling , Goto Yusuke , Haft Sunny , Fukusumi Takahito , Ando Mizuo , Saito Yuki , Guo Theresa , Tamayo Pablo , Yeerna Huwate , Kim William , Hubbard Jacqueline , Sharabi Andrew B. , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

List of dysregulated pathways in patients with cannabinoid metabolites compared with patients without cannabinoid metabolites.
Figure S6 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
Authors: Faramand Rawan , Jain Michael , Staedtke Verena , Kotani Hiroshi , Bai Renyuan , Reid Kayla , Lee Sae Bom , Spitler Kristen , Wang Xuefeng , Cao Biwei , Pinilla Javier , Lazaryan Aleksander , Khimani Farhad , Shah Bijal , Chavez Julio C. , Nishihori Taiga , Mishra Asmita , Mullinax John , Gonzalez Ricardo , Hussaini Mohammad , Dam Marian , Brandjes Brigett D. , Bachmeier Christina A. , Anasetti Claudio , Locke Frederick L. , Davila Marco L.
Published: April 2023

Myeloid and Tregs associated with severe CRS in patients treated with axi-cel.
Table S1 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Authors: Narasimhan Vignesh , Wright Josephine A. , Churchill Michael , Wang Tongtong , Rosati Rachele , Lannagan Tamsin R.M. , Vrbanac Laura , Richardson Anne B. , Kobayashi Hiroki , Price Timothy , Tye Gayle X.Y. , Marker Julie , Hewett Peter J. , Flood Michael P. , Pereira Shalini , Whitney G. Adam , Michael Michael , Tie Jeanne , Mukherjee Siddhartha , Grandori Carla , Heriot Alexander G. , Worthley Daniel L. , Ramsay Robert G. , Woods Susan L.
Published: April 2023

Summary of drug panels and peritonoid genomic information